Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort
Authors:
- Samy SlimaniSSSamy Slimani
- Cédric LukasCLCédric Lukas
- Bernard CombeBCBernard Combe
- Jacques MorelJMJacques Morel
- 1 October 2011
- journal article
- Published by Elsevier in Joint Bone Spine
- Vol. 78 (5) , 484-487
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: Observational study of 30 cases in everyday practiceJoint Bone Spine, 2010
- Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysisArthritis & Rheumatism, 2007
- Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.Blood, 2006
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationBlood, 2001
- Peripheral T-Cell Lymphoma Following Rituximab Therapy for B-Cell LymphomaBlood, 1999
- Peripheral T-cell lymphoma after anti-CD20 antibody therapy.Journal of Clinical Oncology, 1998
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994